SAPHYR (NCT03600818) was a randomized, double-blind, placebo-controlled phase 3 study, investigating the efficacy and safety of sarilumab in polymyalgia rheumatica. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discussed the aims, design, eligibility criteria and findings of the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)‘ (Abstract number: 1676) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is the rationale for the use of sarilumab in the treatment of PMR?
- What were the aims, design and eligibility criteria of the SAPHYR study? (1:18)
- What was the primary endpoint of the study and how well was it achieved? (4:49)
- What were the safety and quality of life findings of the study? (6:11)
Disclosures:Â Bhaskar Dasgupta discloses consulting for Sanofi; receiving grant/ research support from Sanofi; and receiving honoraria from Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2022.
